Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.4951
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 95828515200.0
- FreeCF/Share 7.1636
- PFCF 6.5735
- PE 18.9756
- Debt/Assets 0.5379
- DivYield 0.0523
- ROE 0.2957
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).
Read More
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
Published: September 08, 2025 by: Reuters
Sentiment: Positive
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.
Read More
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hodgkin lymphoma called Breyanzi reached $344 million in Q2 2025, increasing by more than 100% year-on-year. Moreover, Bristol-Myers may expand its label on December 5, 2025, and become the first CAR T-cell therapy in the treatment of relapsed/refractory marginal zone lymphoma.
Read More
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Negative
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in its legacy segment. Notably, BMY's robust profitability and a sector-leading dividend yield help to secure buy-in from income investors with the patience to ride out the near-term turbulence.
Read More
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
Read More
7 Big Yields From The Beat-Up Healthcare Sector
Published: September 01, 2025 by: Forbes
Sentiment: Neutral
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
Read More
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
Read More
Final Trades: ServiceNow, Bristol Myers and Live Nation
Published: August 21, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J.
Read More
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Read More
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with patient investors well rewarded with rich dividend yields, pending growth acceleration.
Read More
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding, but heavy reliance on Eliquis and Opdivo, both facing patent expiries, clouds the outlook. Key upcoming data catalysts and a new CMO offer hope, yet recent drug launches and acquisitions have underperformed expectations.
Read More
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointment, though early signs of the performance of acquired treatment Cobenfy are positive. Underwhelming earnings since last year, along with revenues that are still coming back in form could explain the loss of price momentum for BMY despite otherwise healthy stock metrics.
Read More
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
Read More
PCE Comes in Warmer Than Expected
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
PCE Comes in Warmer Than Expected.
Read More
Economy Heating Up on PCE for June
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
Read More
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Published: July 30, 2025 by: Forbes
Sentiment: Neutral
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements can provide valuable insights.
Read More
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Read More
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100